By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Therapeutic radiopharmaceuticals > Pluvicto
Therapeutic radiopharmaceuticals

Pluvicto

https://themeditary.com/drug/pluvicto-2800.html
Medically Reviewed by Judith Stewart, BPharm TheMediTary.Com | Reviewed: Jul 13, 2023  Additional Content by TheMediTary.Com

Generic name: lutetium lu 177 vipivotide tetraxetan

Drug class: Therapeutic radiopharmaceuticals

Dosage form: injection, for intravenous use

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Pluvicto?

Pluvicto is a targeted radiopharmaceutical treatment for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body.

Pluvicto is used in patients who have already been treated with other anti-cancer treatments.

Patients will need a scan before receiving Pluvicto, using Locametz or another approved PSMA-11 imaging agent to identify the PSMA-positive lesions.

Warnings

Pluvicto may cause harm to an unborn baby.

Men with female partners should use effective contraception for intercourse during treatment with Pluvicto, and for 14 weeks after the last dose.

Pluvicto may cause temporary or permanent infertility in males.

Pluvicto contributes to your overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer.

To minimize radiation exposure to others after you receive Pluvicto

  • you should limit close contact (less than 3 feet) with household contacts for 2 days or with children and pregnant women for 7 days
  • you should refrain from sexual activity for 7 days
  • you should sleep in a separate bedroom from household contacts for 3 days, from children for 7 days, and from pregnant women for 15 days.

Pluvicto can cause severe and life-threatening myelosuppression, including anemia, thrombocytopenia, leukopenia, and neutropenia. 

Pluvicto can cause severe renal toxicity. You should remain well hydrated and urinate frequently before and after administration of Pluvicto to prevent kidney injury. You will receive kidney function tests before and during your treatment.

How should I take Pluvicto

Before you receive Pluvicto, you will receive a scan to identify the tumors that express PSMA.

Pluvicto is a radiopharmaceutical and your healthcare provider will take appropriate safety measures to minimize radiation exposure including the wearing of waterproof gloves and effective radiation shielding.

Pluvicto is administered via intravenous injection every 6 weeks for up to 6 doses, or until disease progression or unacceptable toxicity.

Before administration of Pluvicto patients should drink plenty of water in order to urinate as often as possible during the first hours after administration.

Dosing information

Usual Adult Dosage for Prostate Cancer

- 7.4 GBq (200 mCi) every 6 weeks for up to 6 doses.

- Use: treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

Detailed Pluvicto dosage information
Pluvicto Dosage information (more detail)

Before Taking

You should not receive Pluvicto if you are allergic to lutetium Lu 177 vipivotide tetraxetan.

Pluvicto pregnancy and breastfeeding warnings (more detail)

Before you receive Pluvicto

Before you receive Pluvicto, tell your doctor if you:

  • have low blood cell counts (hemoglobin, white blood cell count, absolute neutrophil count, platelet count)
  • have signs of myelosuppression (tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty stopping bleeding, or frequent infections with signs such as fever, chills, sore throat, or mouth ulcers)
  • have kidney problems
  • have any other type of cancer or treatment for cancer. Pluvicto contributes to long-term cumulative radiation exposure.
  • have a female partner who is pregnant or planning to become pregnant. All radiopharmaceuticals, including Pluvicto, have the potential to cause harm to an unborn baby. Patients should use effective contraception for intercourse during treatment with Pluvicto, and for 14 weeks after the last dose. Pluvicto may cause temporary or permanent infertility in males.

Pluvicto side effects

Pluvicto may cause serious side effects including:

  • Myelosuppression. Contact your healthcare provider if you experience any signs or symptoms of myelosuppression, such as tiredness, weakness, pale skin, shortness of breath, bleeding or bruising more easily than normal or difficulty to stop bleeding, or frequent infections with signs, such as fever, chills, sore throat or mouth ulcers. 
  • Renal Toxicity. Contact your healthcare provider if you experience any signs or symptoms of renal toxicity such as passing urine less often than usual or passing much smaller amounts of urine than usual.

Common side effects may include:

  • fatigue
  • dry mouth
  • nausea
  • anemia
  • decreased appetite
  • constipation.
See more: Pluvicto Side Effects

What other drugs will affect Pluvicto?

Pluvicto is not thought to interact with other medicines.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

More about Pluvicto (Lutetium lu 177 vipivotide tetraxetan)

Dosage information
Pluvicto Side Effects
During pregnancy
Pluvicto Prescribing Information
Drug images
Side effects
Drug class: Therapeutic radiopharmaceuticals

Related treatment guides

Prostate Cancer
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by